 Immunocompromised Host
"Immunocompromised Host" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A human or animal whose immunologic mechanism is deficient because of an immunodeficiency disorder or other disease or as the result of the administration of immunosuppressive drugs or radiation.
| Descriptor ID |
D016867
|
| MeSH Number(s) |
G12.470
|
| Concept/Terms |
Immunocompromised Host- Immunocompromised Host
- Host, Immunocompromised
- Hosts, Immunocompromised
- Immunocompromised Hosts
- Immunocompromised Patient
- Immunocompromised Patients
- Patient, Immunocompromised
- Patients, Immunocompromised
- Immunosuppressed Host
- Host, Immunosuppressed
- Hosts, Immunosuppressed
- Immunosuppressed Hosts
|
Below are MeSH descriptors whose meaning is more general than "Immunocompromised Host".
Below are MeSH descriptors whose meaning is more specific than "Immunocompromised Host".
This graph shows the total number of publications written about "Immunocompromised Host" by people in this website by year, and whether "Immunocompromised Host" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 2 | 2 | | 1995 | 0 | 1 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 2 | 2 | | 1999 | 4 | 1 | 5 | | 2000 | 1 | 4 | 5 | | 2001 | 1 | 0 | 1 | | 2003 | 4 | 3 | 7 | | 2004 | 0 | 5 | 5 | | 2005 | 2 | 4 | 6 | | 2006 | 1 | 3 | 4 | | 2007 | 0 | 4 | 4 | | 2008 | 4 | 3 | 7 | | 2009 | 4 | 1 | 5 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 5 | 6 | | 2012 | 3 | 2 | 5 | | 2013 | 3 | 3 | 6 | | 2014 | 3 | 1 | 4 | | 2015 | 3 | 7 | 10 | | 2016 | 5 | 4 | 9 | | 2017 | 2 | 5 | 7 | | 2018 | 6 | 6 | 12 | | 2019 | 5 | 7 | 12 | | 2020 | 1 | 6 | 7 | | 2021 | 5 | 3 | 8 | | 2022 | 1 | 2 | 3 | | 2024 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunocompromised Host" by people in Profiles.
-
Henao-Mart?nez AF, Olivo Freites C, Agudelo Higuita NI, Marcos LA, Chastain DB, Mohareb AM, Tuells J, Villalpando-Carrion S, Franco-Paredes C. Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States-A Multicenter Network Analysis. Am J Trop Med Hyg. 2024 Jul 03; 111(1):89-92.
-
Bergin SP, Chemaly RF, Dadwal SS, Hill JA, Lee YJ, Haidar G, Luk A, Drelick A, Chin-Hong PV, Benamu E, Khawaja F, Nanayakkara D, Papanicolaou GA, Small CB, Fung M, Barron MA, Davis T, McClain MT, Maziarz EK, Madut DB, Bedoya AD, Gilstrap DL, Todd JL, Barkauskas CE, Bigelow R, Leimberger JD, Tsalik EL, Wolf O, Mughar M, Hollemon D, Duttagupta R, Lupu DS, Bercovici S, Perkins BA, Blauwkamp TA, Fowler VG, Holland TL. Plasma Microbial Cell-Free DNA Sequencing in Immunocompromised Patients With Pneumonia: A Prospective Observational Study. Clin Infect Dis. 2024 03 20; 78(3):775-784.
-
Mancon A, Rizzo A, Mileto D, Grosso S, Foschi A, Cutrera M, Capetti A, Faggion I, Anselmo A, Monte A, Fillo S, Rizzardini G, Gismondo MR, Micheli V. Viro-immunological evaluation in an immunocompromised patient with long-lasting SARS-CoV-2 infection. Emerg Microbes Infect. 2022 Dec; 11(1):786-789.
-
Thornton CS, Huntley K, Berenger BM, Bristow M, Evans DH, Fonseca K, Franko A, Gillrie MR, Lin YC, Povitz M, Shafey M, Conly JM, Tremblay A. Prolonged SARS-CoV-2 infection following rituximab treatment: clinical course and response to therapeutic interventions correlated with quantitative viral cultures and cycle threshold values. Antimicrob Resist Infect Control. 2022 02 05; 11(1):28.
-
Tenforde MW, Patel MM, Gaglani M, Ginde AA, Douin DJ, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Johnson NJ, Srinivasan V, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Duggal A, Wilson JG, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Botros M, Lauring AS, Shapiro NI, Halasa N, Chappell JD, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Rhoads JP, Lindsell CJ, Hart KW, Zhu Y, Naioti EA, Adams K, Lewis NM, Surie D, McMorrow ML, Self WH. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71(4):118-124.
-
DeVine MN, Maxwell S, Haynes AS, MacBrayne CE, Boguniewicz J. Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19. J Pediatr Hematol Oncol. 2022 01 01; 44(1):e293-e295.
-
Craddock AP, Gru AA, Mannschreck D, Wilson BB, Raghavan SS. Primary Cutaneous Monomorphic Post-transplant Lymphoproliferative Disorder Mimicking Squamous Cell Carcinoma In Situ. Am J Dermatopathol. 2021 Dec 01; 43(12):e234-e236.
-
Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, Dascomb K, Ong TC, Klein NP, Liao IC, Grannis SJ, Han J, Stenehjem E, Dunne MM, Lewis N, Irving SA, Rao S, McEvoy C, Bozio CH, Murthy K, Dixon BE, Grisel N, Yang DH, Goddard K, Kharbanda AB, Reynolds S, Raiyani C, Fadel WF, Arndorfer J, Rowley EA, Fireman B, Ferdinands J, Valvi NR, Ball SW, Zerbo O, Griggs EP, Mitchell PK, Porter RM, Kiduko SA, Blanton L, Zhuang Y, Steffens A, Reese SE, Olson N, Williams J, Dickerson M, McMorrow M, Schrag SJ, Verani JR, Fry AM, Azziz-Baumgartner E, Barron MA, Thompson MG, DeSilva MB. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
-
Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, Olson SM, Talbot HK, Casey JD, Mohr NM, Zepeski A, McNeal T, Ghamande S, Gibbs KW, Files DC, Hager DN, Shehu A, Prekker ME, Erickson HL, Gong MN, Mohamed A, Henning DJ, Steingrub JS, Peltan ID, Brown SM, Martin ET, Monto AS, Khan A, Hough CL, Busse LW, Ten Lohuis CC, Duggal A, Wilson JG, Gordon AJ, Qadir N, Chang SY, Mallow C, Rivas C, Babcock HM, Kwon JH, Exline MC, Halasa N, Chappell JD, Lauring AS, Grijalva CG, Rice TW, Jones ID, Stubblefield WB, Baughman A, Womack KN, Lindsell CJ, Hart KW, Zhu Y, Mills L, Lester SN, Stumpf MM, Naioti EA, Kobayashi M, Verani JR, Thornburg NJ, Patel MM. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1337-1343.
-
Dolan SA, Mulcahy Levy J, Moss A, Pearce K, Butler M, Jung S, Dominguez SR, Mwangi E, Maloney K, Rao S. SARS-CoV-2 persistence in immunocompromised children. Pediatr Blood Cancer. 2021 12; 68(12):e29277.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|